Moderna’s stock is poised for further volatility, with analysts cautioning investors that the current share price is built on an assumption of extraordinary future successes that may not materialize. Despite recent sharp declines, the biotech giant’s valuation continues to reflect a scenario where its pipeline drugs achieve blockbuster status and its COVID-19 vaccine maintains unparalleled market dominance, a prospect that appears increasingly optimistic given the evolving landscape of infectious diseases and competitive drug development. This disconnect between current market expectations and the inherent uncertainties of pharmaceutical innovation creates a precarious situation, suggesting that any stumble in clinical trials, regulatory approvals, or market penetration could trigger significant downward price revisions, leading to substantial ‘whiplash’ for shareholders who have bought in at elevated levels.
Adapted from: WSJ.com: Markets
